Evidence map›Paper›PMID 33413197›Full record

ArticleBMC infectious diseases2021

Serological diagnosis and prevalence of HIV-1 infection in Russian metropolitan areas.

D E Kireev, V P Chulanov, G A Shipulin, A V Semenov, E V Tivanova, N M Kolyasnikova, E B Zueva, V V Pokrovskiy, C Galli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

D E KireevFederal Budget Institute of Science Central Research Institute of Epidemiology Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Novogireyevskaya St., 3A, 111123, Moscow, Russia. dmitkireev@yandex.ru.
V P ChulanovFederal Budget Institute of Science Central Research Institute of Epidemiology Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Novogireyevskaya St., 3A, 111123, Moscow, Russia.
G A ShipulinCenter of Strategical Planning and Management of Biomedical Health Risks of the Ministry of Health, Moscow, Russia.
A V SemenovSt. Petersburg Pasteur Research Institute of Epidemiology and Microbiology, St. Petersburg, Russia.
E V TivanovaFederal Budget Institute of Science Central Research Institute of Epidemiology Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Novogireyevskaya St., 3A, 111123, Moscow, Russia.
N M KolyasnikovaFederal Budget Institute of Science Central Research Institute of Epidemiology Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Novogireyevskaya St., 3A, 111123, Moscow, Russia.
E B ZuevaSt. Petersburg Pasteur Research Institute of Epidemiology and Microbiology, St. Petersburg, Russia.
V V PokrovskiyFederal Budget Institute of Science Central Research Institute of Epidemiology Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Novogireyevskaya St., 3A, 111123, Moscow, Russia.
C GalliAbbott Diagnostics, Rome, Italy.
Central Research Institute of Epidemiology · RUSaint Petersburg Pasteur Institute · RUFederal Service for Surveillance on Consumer Rights Protection and Human Wellbeing · RUMinistry of Health of the Russian Federation · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHIV infection is a major health problem in Russia. We aimed to assess HIV prevalence in different population groups and to compare the characteristics of 4th generation immunoassays from Abbott, Bio-Rad, Vector-Best, Diagnostic Systems, and Medical Biological Unit.

methodsThe study included 4452 individuals from the general population (GP), 391 subjects at high risk of HIV infection (HR) and 699 with potentially interfering conditions. HIV positivity was confirmed by immunoblot and by HIV RNA, seroconversion and virus diversity panels were also used. HIV avidity was employed to assess recent infections.

resultsThe prevalence in GP was 0.40%, higher in males (0.62%) and in people aged < 40 years (0.58%). Patients attending dermo-venereal centers and drug users had a high prevalence (34.1 and 58.8%). Recent infections were diagnosed in 20% of GP and in 4.2% of HR. Assay sensitivity was 100% except for one false negative (99,54%, MBU). Specificity was 99.58-99.89% overall, but as low as 93.26% on HR (Vector-Best). Small differences on early seroconversion were recorded. Only the Abbott assay detected all samples on the viral diversity panel.

conclusionHIV infection rate in the high-risk groups suggests that awareness and screening campaigns should be enhanced. Fourth generation assays are adequate but performance differences must be considered.

Indexed as

AdolescentAdultAgedCitiesDrug UsersFemaleHIV-1HIV InfectionsHumansImmunoassayMaleMiddle AgedPregnancyPregnancy Complications, InfectiousPrevalenceRussia4th generation HIV immunoassaysAssay performanceEpidemiologyHigh risk groupsHIV infectionRecent infections

Identifiers

PMID33413197
PMCPMC7791727
OpenAlexW3118825065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.